The Israeli company Betalin Therapeutics, specialized in fabric engineering to cure diabetes, has been chosen as the most innovative biopharmacology company of the year in the launch competition of the Biomed Tel Aviv Mixiii Conference.
Based on Ramat Gan, Betalin Therapeutics develops micro pancreas (EMP), a novel technology that provides significant levels of insulin secretion regulated by glucose for long periods of time.
The objective of Betalin Therapeutics is to provide effective treatment to diabetics by implementing their engineering pancreas that has the ability to detect blood sugar levels.
The micro-pancreas is prepared in the laboratory using a complex natural micro-andamium and all the various cellular components present in the normal endocrine pancreas.
These cells reconstruct the internal insulin production capacity of the body according to blood sugar levels.The micro-pancreas constitutes an autonomous unit that can be practically implemented anywhere in the body.
Once implanted, it becomes vascularized, potentially releasing diabetic patients from the need to constantly monitor their blood sugar levels.
Attempts to treat diabetes by pancreatic beta transplantAbout 50% of patients continue to depend on insulin a year after transplantation, and only about 10% remain independent of insulin five years after transplantation.
The EMP of Betalin Therapeutics is based on the premise that for beta cells they work properly, it is necessary to provide an adequate connective tissue frame that ensures the long -term survival of the cells.The patented platform technology was developed by Prof. Eduardo Mitrani, the Department of Cell Biology and the Development of the Hebrew University of Jerusalem.
In preclinical studies in an animal diabetes model, published in PLOS One, approximately 70% of the mice in which the EMM was implemented did not need more insulin injections even during the longest period tested 90 days after the implementation.
